MEDSECUREAN.COM for INDIAN PHARMACEUTICAL ALLIANCE(FORMERLY INDIAN PHARMACEUTICAL ASSOCIATION)
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 13, 2026 | $900,000 | Replaced |
| 2nd Quarter - Amendment (this page) | Jul 13, 2026 | $90,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
National Security - Medicine Security Health Care Transparency Generics First Generic Market Sustainability Affordable Medicine Partership Trade
Foreign entity interest: The Indian Pharmaceutical Alliance (IPA) is an Indian trade association representing leading multinational pharmaceutical companies, many of which maintain a significant physical and commercial presence in the United States through their North American subsidiaries. As essential partners in Americas medicine supply chain, IPA member companies manufacture nearly 50 percent of the affordable medicines used by patients in the United States. IPA and its members seek to deepen their partnership with the U.S. government and industry to strengthen health and medicine security in both the United States and India, reduce dependence on countries of concern, and build more secure, diversified, and resilient pharmaceutical supply chains. U.S. invited IPA members to two Round Tables at USASelect to discuss working together to reshore affordable medicine and inputs and to discuss U.S. market reforms to drive onshoring.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN JAEGER | — |
Trade (domestic/foreign) TRD
U.S. - India Affordable Medicine Patnership
Foreign entity interest: The Indian Pharmaceutical Alliance (IPA) is an Indian trade association representing leading multinational pharmaceutical companies, many of which maintain a significant physical and commercial presence in the United States through their North American subsidiaries. As essential partners in Americas medicine supply chain, IPA member companies manufacture nearly 50 percent of the affordable medicines used by patients in the United States. IPA and its members seek to deepen their partnership with the U.S. government and industry to strengthen health and medicine security in both the United States and India, reduce dependence on countries of concern, and build more secure, diversified, and resilient pharmaceutical supply chains. At the request of the U.S. government, IPA discussed US-India Affordable Partnership during two different round tables set up by the U.S. government.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN JAEGER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.